{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:43:33Z","timestamp":1789746213154,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,15]]},"DOI":"10.7759\/cureus.48859","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T21:06:18Z","timestamp":1700082378000},"source":"Crossref","is-referenced-by-count":2,"title":["Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report"],"prefix":"10.7759","author":[{"given":"Rakan","family":"Abulnaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-1755. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al.. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018, 71:1755-1764. 10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000261","article-title":"Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"8","author":"Dolladille C","year":"2020","unstructured":"Dolladille C, Ederhy S, Allouche S, et al.. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020, 8:10.1136\/jitc-2019-000261","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.04.007","article-title":"Late-onset immunotherapy-induced myocarditis 2 years after checkpoint inhibitor initiation","volume":"4","author":"Nguyen AT","year":"2022","unstructured":"Nguyen AT, Berry GJ, Witteles RM, Le DT, Wu SM, Fisher GA, Zhu H. Late-onset immunotherapy-induced myocarditis 2 years after checkpoint inhibitor initiation. JACC Cardio Oncol. 2022, 4:727-730. 10.1016\/j.jaccao.2022.04.007","journal-title":"JACC Cardio Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, et al.. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016, 2:234-240. 10.1001\/jamaoncol.2015.4368","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol. 2021, 39:4073-4126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang L","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, et al.. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020, 141:2031-2034. 10.1161\/CIRCULATIONAHA.119.044703","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-1238. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.043","article-title":"Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials","volume":"148","author":"Agostinetto E","year":"2021","unstructured":"Agostinetto E, Eiger D, Lambertini M, et al.. Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials. Eur J Cancer. 2021, 148:76-91. 10.1016\/j.ejca.2021.01.043","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0452","article-title":"Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients","volume":"23","author":"Sarocchi M","year":"2018","unstructured":"Sarocchi M, Grossi F, Arboscello E, et al.. Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist. 2018, 23:936-942. 10.1634\/theoncologist.2017-0452","journal-title":"Oncologist"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li BT","year":"2016","unstructured":"Li BT, Ross DS, Aisner DL, et al.. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol. 2016, 11:414-419. 10.1016\/j.jtho.2015.10.025","journal-title":"J Thorac Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila ME","year":"2012","unstructured":"Arcila ME, Chaft JE, Nafa K, et al.. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012, 18:4910-4918. 10.1158\/1078-0432.CCR-12-0912","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li BT","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, et al.. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022, 386:241-251. 10.1056\/NEJMoa2112431","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3709","article-title":"Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer","volume":"2","author":"Dang C","year":"2016","unstructured":"Dang C, Guo H, Najita J, et al.. Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer. JAMA Oncol. 2016, 2:29-36. 10.1001\/jamaoncol.2015.3709","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer MS","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005, 23:7820-7826. 10.1200\/JCO.2005.13.300","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond EH","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, et al.. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353:1673-1684. 10.1056\/NEJMoa052122","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/204474-stage-4-non-small-cell-lung-cancer-with-human-epidermal-growth-factor-receptor-2-alterations-and-myocarditis-induced-by-immune-checkpoint-inhibitors-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:44Z","timestamp":1707509504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/204474-stage-4-non-small-cell-lung-cancer-with-human-epidermal-growth-factor-receptor-2-alterations-and-myocarditis-induced-by-immune-checkpoint-inhibitors-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.48859","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,15]]}}}